Asset Details
Do you wish to reserve the book?
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries version 1; peer review: 2 approved
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries version 1; peer review: 2 approved
Do you wish to request the book?
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries version 1; peer review: 2 approved
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries version 1; peer review: 2 approved
2016
Overview
Globally, group B
Streptococcus (GBS) remains the leading cause of sepsis and meningitis in young infants, with its greatest burden in the first 90 days of life. Intrapartum antibiotic prophylaxis (IAP) for women at risk of transmitting GBS to their newborns has been effective in reducing, but not eliminating, the young infant GBS disease burden in many high income countries. However, identification of women at risk and administration of IAP is very difficult in many low and middle income country (LMIC) settings, and is not possible for home deliveries. Immunization of pregnant women with a GBS vaccine represents an alternate pathway to protecting newborns from GBS disease, through the transplacental antibody transfer to the fetus in utero. This approach to prevent GBS disease in young infants is currently under development, and is approaching late stage clinical evaluation.
This manuscript includes a review of the natural history of the disease, global disease burden estimates, diagnosis and existing control options in different settings, the biological rationale for a vaccine including previous supportive studies, analysis of current candidates in development, possible correlates of protection and current status of immunogenicity assays. Future potential vaccine development pathways to licensure and use in LMICs, trial design and implementation options are discussed, with the objective to provide a basis for reflection, rather than recommendations.
Publisher
Faculty of 1000 Ltd,F1000Research,F1000 Research Ltd
